secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001493152-23-015936
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 4.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics cuts workforce 17%, accelerates cash flow positive target to Q1 2024
--------------------------------------------------------------------------------

- Reduced workforce by approximately 17% as part of operational efficiency initiatives.
- Now expects to achieve positive cash flow by Q1 2024, a full quarter earlier than prior mid-2024 guidance.
- Revenues expected to be relatively flat sequentially in H1 2023, with growth acceleration starting Q3 2023.
- Dismissed Plante & Moran as auditor; engaged Moss Adams LLP effective May 3, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223015936/0001493152-23-015936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315223015936/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-015936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer